Theratechnologies Inc T.TH

Italy

[scarlet1967]

This recent recruit was hired this month, so they are preparing to launch Trogarzo in Italy.
https://www.linkedin.com/in/massimo-ferro-1516a762

[scarlet1967]

https://www.gazzettaufficiale.it/eli/id/2021/10/19/21A06097/SG    

[scarlet1967]

"packaging: «200 mg - concentrate for solution for infusion - intravenous use - vial (glass) - 1.33 ml (150 mg / ml) »2 vials - AIC n. 048255018 / E (base 10);     reimbursement class: H;      ex factory price (excluding VAT): euro 2,000.00;      retail price (VAT included): € 3,300.80.”

[SPCEO1]

I think I will need to hire an Italian lawyer to actually figure out what the annual revenues from one Italian patient on Trogarzo for a year might be! They also mentioned discounts but it is not clear to me what those discounts might be and there seemed to be other circumstances that might impact the price. But figuring all that out seems like a lot of work and that you need to know someone

[Wino115]

I think we can go with Paul's "...it was a good price..." !  Certainly not US levels, but probably not below 50%.  It had always sounded to me like they thought they could get 75-80% of US price and the Viiv product provided a bit of an umbrella to that as well. 

[scarlet1967]

    I don’t know what the reimbursement H class means versus retail price but 2000 euros equals US $2328. Compared with the US pricing excluding VAT(tax in Italy 22%) it seems it’s about 13% cheaper in Italy.   “The cost for Trogarzo intravenous solution (200 mg/1.33 mL) is around $2,671 for a supply of 2.66 milliliters. The annual list price for every two

[SPCEO1]

If it is only a 13% discount, that is better than I would have expected. Actually much better. And since the deceline in US sales of Trogarzo has been faster than I expected, that is very helpful as TH tries to hold the line with Trogarzo total sales. Previously, I thought Trogarzo sales in the US would fall off only marginally and that total Trogarzo sales would grow. Now I am not as confident in

[scarlet1967]

The IV push trial costing  $2M could be a good reference as per the cost of the IM trial which THTX has to cover now I think in terms of patients compliance or new patients starting the treatment the IM is much more patient friendly so that extra $2M to me is worth the investment. As per competition I think the company has to use the long lasting efficacy almost a decade now to market the

[SPCEO1]

I think we need to think in terms of whether the IM version would be able to slow the decline of Trogarzo sales enough to justify the expense rather than if it would add to sales. I just cannot see Trogarzo injections winning new patients over Viiv and GILD pills, no matter how long lasting the injections are or how easy it might be for the patient. The patient still has to show up at the doctors

[qwerty22]

It's really hard to see where the upside is with Trogarzo. It definitely feels like a moment where the company should be re-asssessing their relationship with this drug. It's not just the cost of the IM trial, it continues to be a pre-occupation of the analysts and I'd agree with you it seems more like to be generating negative headlines rather than positive ones. Maybe they believe

[SPCEO1]

I suspect TH will struggle to make the right call with Trogarzo simply because Paul is a sales guy and he is sure he can come up with a plan that will get those Trogarzo sales headed higher. And, who knows, maybe he can. He seems to be having some limited success with reinvigorating Egrifta sales so maybe we should give him the benefit of the doubt for now. But he is in a difficult battle against

[SPCEO1]

I should have noted that the always questionable sales estimator from Bloomberg shows US Trogarzo sales picked up a little in September while Egrifta sales slipped from August's level. 

[palinc2000]

Read Dubuc s comment on Trogarzo's pick up since the start of the 4 th quarter 16:47 Sales of Trogarzo for the quarter were down seven point eight percent compared to last year and came in six point six million dollars. As mentioned in the past, Trogarzo with new prescriptions had been more impacted by COVID as patients have been more reluctant to visit healthcare facilities. Sales were also

[SPCEO1]

Covid was still an issue in the US in September and the competition was unchanged. So, any pick-up is a helpful sign given the conditions Trogarzo is facing but the trend is still a negative one in the US. Maybe European sales will ramp up faster than US sales will fall off, that certainly seems possible. And maybe the negative trend was just from the intial impact of Viiv's drug and the

[scarlet1967]

I am not familiar with the insurance policies in the US but it seems there is a risk for out of pocket costs for patients. So the drug's price might put off some patients. Here in Canada and in The UK as far as I know any IM administration has to be done by trained health care providers maybe that's not the case in the US or other European countries. I recall also Paul mentioned some

[SPCEO1]

That risk of out-of-pocket costs is normally quite small in the US. If a Medicare recipient does not have supplemental insurance that covers most of the 20% Medicare does not cover, then they typically get price breaks from the drug manufacturer as the drug maker is interested in at elast getting the 80% of the drug's price that Medicare wil cover. Now, my wife is on Medicare and she has to